Tompkins Financial’s Charles River Laboratories CRL Stock Holding History

Tompkins Financial’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-122	Closed	-$18K	–	359
2019 Q1	$18K	Hold	122	–	–	﹤0.01%	314
2018 Q4	$14K	Sell	122 -77	-39%	-$9.64K	﹤0.01%	318
2018 Q3	$27K	Sell	199 -86	-30%	-$10.6K	0.01%	295
2018 Q2	$32K	Hold	285	–	–	0.01%	292
2018 Q1	$30K	Buy	+285	New	+$30.7K	0.01%	284
2017 Q4	–	Sell	-45	Closed	-$5K	–	402
2017 Q3	$5K	Buy	+45	New	+$4.62K	﹤0.01%	363

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Tompkins Financial's CRL Position: Q2 2019 in Review

Tompkins Financial sold out of Charles River Laboratories (CRL) in Q2 2019, closing a stake of 122 shares — an estimated $18K sold.

Tompkins Financial first reported a position in CRL in Q3 2017 and held it in 6 quarters. The position peaked at $32K in Q2 2018. 405 funds tracked by Wall St. Rank hold CRL as of Q2 2019.

Tompkins Financial reported no remaining Charles River Laboratories position as of Q2 2019 after selling out during the quarter.
Tompkins Financial sold 122 Charles River Laboratories shares in Q2 2019, an estimated $18K.
Tompkins Financial first reported a position in Charles River Laboratories in Q3 2017 and held it in 6 quarters.
Tompkins Financial's Charles River Laboratories position peaked at $32K in Q2 2018.
405 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2019.

Based on Tompkins Financial's 13F filing for Q2 2019, filed 17 Jul 2019.